A quantitative high-throughput gene chip assay, based on nuclease protection, has been developed for drug discovery. The assay permits the expression levels of numerous genes to be measured simultaneously in individual samples. We will use this technology to develop an assay that can measure… More

DESCRIPTION (provided by applicant): The ArrayPlate is a new microplate-based technology for measuring a profile of gene expression now being used for target validation, high throughput screening, and QSAR lead optimization. This Phase I grant proposes to demonstrate that the ArrayPlate,… More

DESCRIPTION (provided by applicant): The identification of gene targets for drug discovery, including AIDS research and mental health, relies heavily on the use of high density array whole genome platforms. It is also true for the discovery of biomarker s for diagnostic assays. The quantitative… More

DESCRIPTION (provided by applicant): The objective of this Phase I 2nd resubmitted proposal is to demonstrate the feasibility of establishing a screening assay and platform (SP-qNPA Microfluidic Screening Platform) that monitors host cell response to detec t exposure to, and provide diagnosis of… More

DESCRIPTION (provided by applicant): Phospholipidosis (PLDosis) or lipid metabolism disorders are a factor in many drug induced liver diseases. Drug induced, dose-dependent, alterations in the expression of sets of genes, whether direct cause or effect, ca n provide a molecular signature of the… More

DESCRIPTION (provided by applicant): This application is a first resubmission of a Phase I application. An area of special interest to NIAID for SBIR/STTR applications is Biomarkers of Host Immune Defense to Bioterrorism Pathogens . The use of microRNA's (miRNA) expressed in white blood cells as… More

DESCRIPTION (provided by applicant): Sequencing is very powerful for identifying differences in genomic DNA that may regulate cell function and diseases, pre-dispose persons to certain diseases, or warn of adverse drug metabolism. It provides a basis for i dentifying differences in gene expression,… More

This Phase I proposal will develop and validate assays to measure the metabolism of compounds  and their affect on liver cells using a multiplexed gene expression assay platform, the quantitative Nuclease  Protection Assay (qNAP¿) that can measure the expression of up to 100 mRNA… More

A molecular test using FFPE tissue from patients to distinguish basal-like breast cancer from other subtypes will be developed and confirmed. The test will be based on a commercial platform, the lysis-on ly quantitative Nuclease Protection Assay (qNPA 1M). Current gene expression signatures… More

DESCRIPTION (provided by applicant): There is currently no good way to screen for early stages of head and neck cancers caused by high risk types of human papillomavirus. The objective of this proposal is to develop a screening assay for dental patients to detect HPV+ head and neck cancer ( HNC )… More

DESCRIPTION (provided by applicant): miRNA biomarkers related to Alzheimer's disease (AD) that may be useful as a diagnostic tool or in elucidating the mechanisms of disease and discovery of novel therapeutics will be identified using a novel whole transcriptome qBead X-MAP-based assay (not… More